Dr. Bhan is a senior pathologist recognized for his diagnostic expertise in breast cancer, and in monitoring transplant and immunodeficiency cases. His current research is focused on IBD and the immunopathogenesis of liver disease. His centers and specialties also include the Center for the Study of Inflammatory Bowel Disease.
- Clinical Interests
- Autopsy Pathology
- Medical Education
- MD, All India Institute of Medical Sciences
- MBBS, Christian Medical College
- Residency, Boston Children's Hospital|Residency, Boston Medical Center
- Board Certifications
- Anatomic Pathology
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
After joining the Immunopathology Unit in 1975, Dr. Bhan performed pioneering work on the application of monoclonal antibodies in the characterization of lymphoid cells in tissues and established the Diagnostic Immunoperoxidase Laboratory in 1981. Dr. Bhan directed the Immunopathology Unit composed of the Immunoperoxidase, Immunofluorescence, Flow Cytometry, and ANCA laboratories for over 15 years. Currently, Dr. Bhan is responsible for evaluation of prognostic markers, including hormone receptors and Her-2/neu FISH analysis of breast cancer cases, and peripheral blood lymphocyte monitoring of transplant patients, and immunodeficiency cases by flow cytometry.
Dr. Bhan's major research interests have been the characterization of cell mediated reactions and mucosal immune responses, and defining the pathogenesis of inflammatory bowel disease. His laboratory has taken a major role in developing experimental models of inflammatory bowel disease using knockout mice. These studies have demonstrated an important role of the appendix in the development of ulcerative colitis-like inflammation in mice and identified regulatory B cells capable of suppressing mucosal inflammation. Dr. Bhan is an Associate Director of the NIH-funded, internationally recognized, Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital. Dr. Bhan is also interested in the immunopathogenesis of liver disease; he has been the pathologist in charge of liver transplant pathology since 1985 and has participated in NIH-supported multicenter studies to evaluate therapy for hepatitis C and hepatitis B.
- Research Summary
My research interests are Mucosal Immunology and Inflammatory Bowel Disease. See details at the Bhan Lab.
- SLAMF4 Is a Negative Regulator of Expansion of Cytotoxic Intraepithelial CD8+ T Cells That Maintains Homeostasis in the Small Intestine. O'Keeffe MS, Song JH, Liao G, De Calisto J, Halibozek PJ, Mora JR,Bhan AK, Wang N, Reinecker HC, Terhorst C. Gastroenterology. 2015 Feb 10. pii: S0016-5085(15)00168-7. doi: 10.1053/j.gastro.2015.02.003. [Epub ahead of print]
- Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Samir AE, Dhyani M, Vij A, Bhan AK, Halpern EF, Méndez-Navarro J, Corey KE, Chung RT. Radiology. 2015 Mar;274(3):888-96. doi: 10.1148/radiol.14140839. Epub 2014 Nov 13.
- Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Lassen KG, Kuballa P, Conway KL, Patel KK, Becker CE, Peloquin JM, Villablanca EJ, Norman JM, Liu TC, Heath RJ, Becker ML, Fagbami L, Horn H, Mercer J, Yilmaz OH, Jaffe JD, Shamji AF, Bhan AK, Carr SA, Daly MJ, Virgin HW, Schreiber SL, Stappenbeck TS, Xavier RJ. Proc Natl Acad Sci U S A. 2014 May 27;111(21):7741-6. doi: 10.1073/pnas.1407001111. Epub 2014 May 12.
55 Fruit Street
Boston, MA 02114-2696